	LEO I	Pharma disclosure report - o	countries without represent	ation by LEO Pharma			
					Dat	te of publication:	: June 30, 202
Full name		Principal Practice Address  Unique country identifier OPTIONAL	Donations and Grants to HCOs	Contribution to costs of Events	Fee for service and consultancy	r	
	HCPs: City of Principal Practice HCOs: city where registered  Country of Principal Practice Principal Practice Address			Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event  Registration Fees Travel & Accommodation	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		TOTAL OPTIONA
INDIVIDUAL NAMED DISCLOSURE - one li	ne per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available fo	or the individual Recipient or public autho	orities' consultation only, as appropriate)				
OTHER, NOT INCLUDED ABOVE - where in	formation cannot be disclosed on an individual basis for legal reasons						
Aggregate amount attributable to transfers of value to such Recipients							1
Number of Recipients in aggregate disclosure							
% of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed							l
INDIVIDUAL NAMED DISCLOSURE - one li	ne per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available fo	for the individual Recipient or public auth	orities' consultation only, as appropriate)				
Health Center 4, Clinic of Esthetic Dermatology and Surgery	Riga Latvia Skanstes str. 50, Building 5, 3rd floor				€ 8.000,00		€ 8.000,00
OTHER, NOT INCLUDED ABOVE - where in	formation cannot be disclosed on an individual basis for legal reasons						
Aggregate amount attributable to transfers of value to such Recipients							
Number of Recipients in aggregate disclosure							
% of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed							1

AGGREGATE DISCLOSURE

Transfers of Value re Research & Development as defined in the EFPIA Code of Practice